Pre-Grant Publication Number: 20110021564
Please help the USPTO examine the application by evaluating the relevance of the publicly submitted prior art to the patent application.
Peer To Patent forwards the Top 10 most relevant prior art submissions and their annotations to the USPTO.
Review this prior art and click on the thumbs up (or down) to indicate whether this submission should be forwarded to the USPTO.
If you login then you can add an annotation by typing in the box at the bottom of the screen to comment on the relevance of the prior art to the claims of the patent application.
Review this prior art and click on the thumbs up (or down) to indicate whether this submission should be forwarded to the USPTO.
If you login then you can add an annotation by typing in the box at the bottom of the screen to comment on the relevance of the prior art to the claims of the patent application.
Prior Art Detail
Summary / Description
| Summary / Description | Benzphetamine (amphetamine prodrug and anorexic drug) has been used as a treatment for obesity since it was approved by the FDA in 1960. In a double blind study, it was found to that there were no differences in weight loss for patients receiving Benzphetamine and D-Amphetamine. Lisdexamphetamine is a D-Amphetamine derivative. |
Basic Information
| Type of Prior Art | Print Publication |
| Publication Title * | A Controlled Clinical Comparison of Benzphetamine and D-Amphetamine in the Management of Obesity |
| Author | Benjamin Simkin, MD and Leon Wallace, MD |
| ISBN | |
| Page Range | 632-637 |
| Medium | Journal article |
| Publication Date * | September 1, 1961 |
| URL | http://www.ajcn.org/content/9/5... |
Notes / To Do
| Notes | Article is from the American Journal of Clinical Nutrition. Benzphetamine is currently marketed by Pfizer under the brand name Didrex. |
Excerpt
Excerpt Finally, if both drugs tested in this study, benzphetamine, and d-amphetamine, were found to be equipotent in anorexigenic activity, and not significantly different in side effects, is there any clinical advantage in introducing another amphetamine drug for the treatment of obesity? The answer is yes. This positive assertion is based upon careful observation of the response of obese private patients to various amphetamine drugs over a period of several years. No one amphetamine drug is effective in all patients. No one drug is free of disturbing side effects in all patients. No single available amphetamine-compound universally produces a significant anorexic effect with an accompanying sense of well-being in all patients. |
Relevance
Claims
1
Relevance
Details the use of an amphetamine prodrug for the treatment of obesity and its comparative effectiveness in obesity treatment to D-amphetamine class drugs.
Details the use of an amphetamine prodrug for the treatment of obesity and its comparative effectiveness in obesity treatment to D-amphetamine class drugs.
Claim Chart
All
0 days left
